Biological MArkers of FRAilty in Elderly Subjects

Elderly Persons Clinical Trial

— MAFRA  

Official title:

PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02816580
• Other study ID #: PO14057
• Status: Completed
• Phase: N/A
• Start date: February 23, 2015
• Est. completion date: October 2, 2019

Study information

• Verified date: February 2022
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Epidemiological data from Europe have shown that around 30% of subjects aged over 65 years of age are pre-frail, and 15% are frail. Recent research has demonstrated that identifying frailty and implementing preventive measures can help to slow cognitive decline. Screening and treating frailty seem to be a good start towards preventing dependency. On the premise that this frailty is the result of more pronounced tissue alterations in certain elderly subjects, assessment of post-translational modification derived products (PTMDP) represents an innovative evaluation method. These include advanced glycation end-products (AGE), and carbamylation-derived products (homocitrulline). Indeed, the intensity of these modifications increases with ageing, and assessing the products resulting from these alterations could show the existence of differences according to frailty status. This would make it possible to adapt treatment accordingly in elderly subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 254
• Est. completion date: October 2, 2019
• Est. primary completion date: October 2, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• With social security coverage
• Accept to participate in the study and sign informed consent for the study and for the collection of biological samples

Exclusion Criteria:

• < 65 yo

Related Conditions & MeSH terms

• Elderly Persons
• Frailty

Intervention

Other:
• Blood collection

Locations

Country	Name	City	State
France	Chu de Reims	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	post-translational modification derived-products (PTMDP) quantification by Multidimensional Chromatography Coupled withTandem Mass Spectrometry (LC/LC-MS/MS)		baseline